The pharma marketing organization of the future will not be measured by how many employees it has. How many agencies it works with. Or how much budget it controls. It will be measured by its ability to influence behavior, improve access, and drive business results.
Marketing brands will keep putting together annual plans. Agencies will keep making media plans. Research companies will keep running research studies. Media partners will keep selling impressions, and analysts will keep pulling up dashboards that tell us what happened. We will all have jobs and budgets. But we’ll keep asking the same question we have always asked. Did we make a difference?
That question will be harder to dodge in the coming years.
I believe we will see huge changes in pharma marketing organizations over the next 3-5 years. AI, commercial pressures, changes in HCP behavior, more empowered patients, and increased scrutiny of promotional spend will force these organizations to think differently not only about how we market our products, but also about how they are built and measured.
It may even mean some marketers discover their skill set no longer matches what their company needs.
Is the brand team dead?
Many pharma marketing organizations today have structures very similar to what they had 15-20 years ago. They include Brand Directors, Product Managers, Digital Marketers, Research Analysts, Agencies, and a variety of functional experts. They will all continue to do many of the same tasks they do today.
These people aren’t bad at what they do. Some of these folks are incredibly smart. The issue is that these organizations are built for a type of marketing that no longer exists.
We will likely have fewer people doing these activities, and more people focused on driving outcomes. Brand teams will still exist, but they’ll focus more on driving customer experience and making business decisions.
As AI becomes more prevalent, these capabilities will take over many tasks that currently take up a significant portion of marketing’s time. These include writing content, pulling research studies, segmenting customers, monitoring prescriber behavior, and executing media plans. These capabilities will allow marketers to focus on higher-value decisions.
A Brand Manager may begin their week with a summary of what occurred in their market. Which customers showed a behavior change, where are patients facing access hurdles, what messaging resonated with customers, what are competitors doing, and, most importantly,y what can we do this week to change our business trajectory? This is a different position.
AI will not replace pharma marketers. It will make bad marketers more obvious.
A narrative is emerging around AI as a productivity enhancer in pharma. That’s true, but I think the bigger conversation around AI will be which assumptions we no longer accept as “the way we do things.”
Why does it take months to launch a media campaign when AI can speed up the process? Why do we keep running similar research studies when we already have data that may provide answers? Why are we still using annual plans to make marketing decisions when we can monitor our customers much more frequently?
Obviously, there will be caveats to all of these statements. We live in a world of medical-legal, regulatory, and Privacy. So AI will not be able to write promotional content for us and push it out to customers. We also won’t be able to input patient-level data into our commercial engines and expect to leverage everything we learn in our marketing programs.
But that does not mean we cannot use these capabilities to improve how we do marketing. I think more organizations will incorporate AI into their day-to-day marketing operations, rather than building an “AI team” that spends most of its time showing off its tech.
What will give organizations an edge is their ability to use these capabilities to make better business decisions.
Customer experience will become a bigger part of the pharma marketing organization.
As these marketing organizations continue to evolve, we will see fewer silos across marketing functions. Currently, teams focus on HCP marketing, patient marketing, digital, research, field, and access. All of which can play a significant role in driving customer behavior.
Customers do not think about pharma marketing that way.
A physician may see a piece of content, look up information about a disease, speak to a sales rep, and research access to a therapy. A patient may see an ad, navigate to our website, speak to their provider, learn they have no access to a therapy,y and never start their treatment.
All of these touch points can impact behavior.
Marketing organizations need to think about how to drive the full customer experience and address issues that prevent target customers from making informed decisions.
“How can we improve our physician email open rate?” may no longer be a question marketing should ask. Instead, marketing will focus on questions like, “How can we get the right HCP to consider our therapy for our target patient population?”
“How many people visited our patient website?” will become “Did our patient learn valuable information that allowed them to have a better conversation with their HCP?”
Access will also become a bigger focus for marketing. We will continue to have Market Access teams that focus on this area. But marketing will need to partner with these teams to identify access hurdles each function can address.
Obviously there will need to be some separation of these functions. But I think we will see them work together in a more meaningful way.
What will this new organization look like?
There will not be one cookie-cutter organization that fits every pharma company. Companies that focus on specialty diseases will have different needs than companies that sell to primary care.
However, we can start to picture what this new organization may look like.
| What they will be focused on | |
|---|---|
| Brand and Portfolio Management | Build strategy for your products. Decide where to invest your dollars and how to grow your business. |
| Customer Experience | Drive the HCP and Patient experience. Ensure the right customer is targeted and receives the right message. |
| Data / Insights / AI | Develop intelligence about your customer base. Create tools that help drive better decisions and experiments. |
| Content & Engagement | Create content in a more modular way.Enables more customization and faster turnaround times. |
| Commercial Effectiveness | Drive incremental business growth. Improve how we measure marketing effectiveness and allocate dollars. |
| Integration with other functions | Work with Medical, Access, and Field to drive better patient and HCP experiences. |
There will be fewer roles focused on certain areas and more that require being a jack-of-all-trades. Someone who knows how to work with an agency will be more valuable than someone who can analyze data and challenge how we do marketing. The best marketers will not be the ones that can create the most campaigns. They will be the ones that know what campaigns we should NOT be running.
How Marketing Will Be Measured is the Biggest Change
This is where it gets a little uncomfortable. We have been measuring all sorts of marketing metrics that are easy to quantify but don’t drive business impact.
Impressions. Clicks. Web Traffic. Email opens. Video views. Number of detail aids handed out. Awareness of campaign. These are not useless metrics. They can help you diagnose whether something is working. But they don’t tell us whether our marketing is making a difference.
Just because a physician opened your email does not mean they will consider your therapy. Just because a patient visited your website doesn’t mean they received the care they needed. You can spend millions of dollars on an ad campaign and not see any incremental business impact.
Marketing will be forced to drive more incremental business in the future. Here are some examples of how we may start to measure performance in the future:
| Metric We Use Today | Metric We May Use In The Future |
|---|---|
| HCP Email Open Rates | Increased HCP engagement that can drive business growth. |
| Website Traffic | Meaningful engagements that drive the right patient actions. |
| Ad Impressions | Increased reach to target customers that drives downstream behaviors. |
| Brand Awareness | Awareness of therapy that can drive incremental business. |
| Rx | Incremental Rx growth that can be attributed to marketing activities. |
| Marketing ROI | Incremental business impact that can be attributed to the total cost of the campaign. |
| Content Created | How effective was the content we created, and can we reuse it to lower costs? |
| Marketing Plan Completion | Were we able to meet our business goals and learn from the data we collected? |
The key word here is incremental. If your Rx grew by 8%, how much of that can be attributed to your marketing efforts? Did we see more coverage? Did your competitor have a shortage? Did guidelines change? Did your sales team work harder? Did we just see growth in our market?
We will continue trying to attribute our efforts to business growth. But attribution will not be the end-all, be-all answer. We need to get better at experimenting with our customers and proving our efforts drove business impact. Sometimes we can’t prove our efforts. Good marketers will know when to stop trying to make data say what we want it to say.
Marketing Will Have To Do More Than Drive Prescriptions
Pharma marketing is not the same as marketing a brand at the grocery store. We cannot measure our success simply by driving more prescription volumes. We need to ensure we provide the right information to the right patients and HCPs. If we increase Rx volume but our patients are not taking the therapy they are prescribed,d then we have failed.
We should also measure our marketing teams on how well they drive customer experience and the patient journey. Do we know that we are targeting the right HCP population? Are our patients receiving information that helps them make informed decisions with their HCP? Are we removing access hurdles that are preventing patients from starting and staying on therapy?
We will not be able to measure everything that our marketing does. But we can hold ourselves accountable to certain actions that drive these outcomes.
The Role Of The CMO Will Continue To Evolve
The CMO will need to become a better steward of their marketing dollars. They will need to know not only why we are investing in certain activities but also when to pull back. They will need to tell Finance where their dollars are going and why.
This will require marketing to work more closely with finance. They will need to show Finance that investing more dollars will yield higher returns. What would you do with an extra $5M? Educate patients? Run more ads? Invest in better content capabilities? Or not spend that dollar?
Good CMOs will know the answer. They will also need to hire better. We need to find people who can think beyond what we are currently doing. Someone who can be creative and make smart business decisions.
Agencies Will Have To Adapt As Well
Agency teams will also have to change how they operate.
We will continue to see agencies provide value to pharma marketing organizations. But how they are paid and how many people are on these teams will change.
Pharma companies will start to ask why we need to pay these high fees for something that AI can help us with. Agencies that can bring unique value to the table will continue to thrive. But agencies that rely on producing more assets faster may see their business decline.
The agency of the future may have fewer people and focus on specific areas of expertise. Similar to marketing teams. Agencies will have to prove that they are making a difference.
Technology Will Not Be The Biggest Roadblock. Mindset Will.
Pharma has abundant data, vendors, and consultants that can help it transform its marketing organizations.
What we lack is the desire to change how we operate.
Annual plans. Functional teams that work in silos. Too many levels of approval. Rewarding activity over outcomes. And people who have built their careers around how we operate today. AI will not fix these issues. Nor will implementing a new martech solution. Or creating a new org chart.
Companies that embrace change will keep growing. They will challenge the status quo and make better business decisions. They will also fail at some things. Instead of covering those failures with vanity metrics,s they will learn from them.
I think we will continue to see changes in pharma marketing organizations over the next few years. By 2030, we will likely have leaner organizations that use AI to make better decisions and deliver a better customer experience. This does not mean that we will spend less money on marketing. Or have fewer people. Some companies may take the money they save by streamlining their organizations and invest it in expanding access or customer support.
But we will use those dollars better.
We will have organizations that are more focused on driving business impact. They will better understand their customers and find ways to improve access to care. The biggest change may be that we will stop telling people what we did.
And start proving that we made a difference.




